+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age-related Macular Degeneration (AMD) - Epidemiology Forecast - 2032- Product Image
Age-related Macular Degeneration (AMD) - Epidemiology Forecast - 2032- Product Image
Sale

Age-related Macular Degeneration (AMD) - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 160 Pages
  • June 2022
  • Region: Global
  • DelveInsight
  • ID: 5524547
UP TO OFF until Dec 31st 2024
Description Jump to:
This ‘Age-related Macular Degeneration (AMD) - Epidemiology Forecast-2032' report delivers an in-depth understanding of Age-related Macular Degeneration (AMD), historical and forecasted epidemiology as well as trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Age-related Macular Degeneration (AMD): Disease Understanding


Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease of elderly individuals that causes a progressive loss of the central vision needed to drive, read, recognize faces, and see the world in color. AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD's exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.

AMD is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. AMD can be classified as early, intermediate, or late based on its clinical features, including drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).

AMD can also be characterized as either dry (atrophic or non-neovascular) or wet (exudative or neovascular).

Age-related Macular Degeneration Diagnosis


AMD rarely causes symptoms in its early stages, annual eye examinations are key to detecting the disease and starting treatments when they are most effective. During an eye exam, the eye healthcare provider checks for changes to the retina and macula. Patients may get one or more of these tests:

  • Visual field test: An Amsler grid has a grid of straight lines with a large dot in the center. The healthcare provider asks to identify lines or sections on the grid that look blurry, wavy, or broken. A lot of distortion may indicate that patient have AMD or the disease is worsening. Patient can use this visual field test at home to monitor vision.
  • Dilated eye exam: Eye drops dilate, or widen, patient pupils. Once patient's eyes are dilated, healthcare provider uses a special lens to look inside patient's eyes.
  • Fluorescein angiography (FA): Healthcare provider injects a yellow dye called fluorescein into a vein in patient's arm. A special camera tracks the dye as it travels through blood vessels in the eye. The photos can reveal any leakage under the macula.
  • Optical coherence tomography (OCT): This imaging machine takes detailed images of the back of the eye, including the retina and macula. Optical coherence tomography isn't invasive or painful. Patient simply look into a lens while the machine takes pictures.
  • Optical coherence tomography angiography (OCTA): This diagnostic tool uses laser light reflection (instead of fluorescein dye) and the OCT scanning device. It takes just a few moments and produces 3D images of blood flow through the eye.

Age-related Macular Degeneration Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment in the scenario of Age-related Macular Degeneration in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Age-related Macular Degeneration Detailed Epidemiology Segmentation

  • In the year 2021, the total prevalent cases of AMD were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2032.
  • The US accounted for approximately 17,282,569 prevalent cases of AMD in the year 2021.
  • In EU-5 countries the highest number of prevalent cases of AMD was observed in Germany with 7,850,793 cases in the year 2021, followed by France.
  • Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.
  • In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.
  • In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple number of folds by 2032.
  • In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age group 50-59 years, 60-69 years, 70-79 years, and ≥80 years respectively. As per the estimates by the publisher, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022-2032.
  • In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50-59 years, 60-69 years, 70-79 years, and ≥ 80 years in 2021.
  • In the US, the total diagnosed cases of dry AMD by stages were approximately 10,499,160 cases for early and intermediate dry AMD and 1,166,573 cases for advanced (geographic atrophy associated with dry AMD) in 2021. As per the analysis, stage-wise cases are also expected to by 2032.
  • In the US, the total geographic atrophy cases by visual impairment were 349,972; 583,287; and 233,315 cases for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2021.

Scope of the Report

  • The report covers the descriptive overview of Age-related Macular Degeneration, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Age-related Macular Degeneration.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM, total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment.

Report Highlights

  • 11-Year Forecast of Age-related Macular Degeneration
  • The 7MM Coverage
  • Total Prevalent Cases of Age-related Macular Degeneration
  • Diagnosed Prevalent Cases of Age-related Macular Degeneration
  • Type-specific Cases of AMD (Dry-AMD, and Wet-AMD)
  • Total Age-specific Cases of AMD (Dry-AMD, and Wet-AMD)
  • Total Diagnosed dry AMD cases by stages
  • Total Geographic Atrophy Cases by Visual Impairment

Key Questions Answered

  • What are the disease risk and burdens of Age-related Macular Degeneration?
  • What is the historical Age-related Macular Degeneration patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Age-related Macular Degeneration at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population about Age-related Macular Degeneration?
  • Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Age-related Macular Degeneration during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy


The Age-related Macular Degeneration report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Age-related Macular Degeneration epidemiology forecast.
  • The Age-related Macular Degeneration epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Age-related Macular Degeneration epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Table of Contents

1. Key Insights2. Report Introduction
3. Age-related Macular Degeneration Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Age-related Macular Degeneration in 2019
3.2. Patient Share (%) Distribution of Age-related Macular Degeneration in 2032
4. Key Events
5. Executive Summary
5.1. Wet AMD
5.2. Dry AMD
6. Disease Background and Overview
6.1. Introduction
6.1.1. Classification and Clinical Manifestation
6.1.2. Signs and Symptoms of AMD
6.1.3. Risk Factors
6.1.4. Pathophysiology of AMD
6.2. Diagnosis
6.3. Diagnostic Guidelines
6.3.1. NICE Guidelines
6.3.2. American Academy of Ophthalmology
6.3.3. Harvard Ophthalmology
6.3.4. European Society of Retina Specialists (EURETINA)
7. Patient Journey8. Key Opinion Leaders' Views
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: 7MM
9.2.1. Prevalent Cases of AMD
9.2.2. Diagnosed Prevalent Cases of AMD
9.2.3. Type-specific cases of AMD
9.2.4. Age-specific Cases of AMD
9.2.5. Dry AMD Cases by Stage
9.2.6. Geographic Atrophy (GA) Cases by Visual Impairment (%)
9.3. Total Prevalent Cases of AMD in the 7MM
9.4. Type-specific Diagnosed Prevalent Cases of AMD in the 7MM
9.5. The United States
9.5.1. Total Prevalent Cases of AMD
9.5.2. Total Diagnosed Cases of AMD
9.5.3. Type-specific Cases of AMD
9.5.4. Total Age-specific Cases of AMD
9.5.5. Total Diagnosed Dry AMD Cases by Stages in the US
9.5.6. Total Geographic Atrophy Cases by Visual Impairment in the US
9.6. EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
9.6.1. Germany
9.6.1.1. Total Prevalent Cases of AMD
9.6.1.2. Total Diagnosed Cases of AMD
9.6.1.3. Type-specific Cases of AMD
9.6.1.4. Total Age-specific Cases of AMD
9.6.1.5. Total Diagnosed Dry AMD Cases by Stage
9.6.1.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.2. France
9.6.2.1. Total Prevalent Cases of AMD
9.6.2.2. Total Diagnosed Cases of AMD
9.6.2.3. Type-specific Cases of AMD
9.6.2.4. Total Age-specific Cases of AMD
9.6.2.5. Total Diagnosed Dry AMD Cases by Stage
9.6.2.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.3. Italy
9.6.3.1. Total Prevalent Cases of AMD
9.6.3.2. Total Diagnosed Cases of AMD
9.6.3.3. Type-specific Cases of AMD
9.6.3.4. Total Age-specific Cases of AMD
9.6.3.5. Total Diagnosed Dry AMD Cases by Stage
9.6.3.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.4. Spain
9.6.4.1. Total Prevalent Cases of AMD
9.6.4.2. Total Diagnosed Cases of AMD
9.6.4.3. Type-specific Cases of AMD
9.6.4.4. Total Age-specific Cases of AMD
9.6.4.5. Total Diagnosed Dry AMD Cases by Stage
9.6.4.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.5. The United Kingdom
9.6.5.1. Total Prevalent Cases of AMD
9.6.5.2. Total Diagnosed Cases of AMD
9.6.5.3. Type-specific Cases of AMD
9.6.5.4. Total Age-specific Cases of AMD
9.6.5.5. Total Diagnosed Dry AMD Cases by Stage
9.6.5.6. Total Geographic Atrophy Cases by Visual Impairment
9.7. Japan
9.7.1. Total Prevalent Cases of AMD
9.7.2. Total Diagnosed Cases of AMD
9.7.3. Type-specific Cases of AMD
9.7.4. Total Age-specific Cases of Wet AMD
9.7.5. Total Diagnosed Dry AMD Cases by Stages in Japan
9.7.6. Total Geographic Atrophy Cases by Visual Impairment Japan
10. Appendix
10.1. Bibliography
10.2. Report Methodology
11. Publisher Capabilities12. Disclaimer13. About the Publisher
List of Tables
Table 1: Summary of Wet AMD, Epidemiology (2019-2032)
Table 2: Summary of Dry AMD, Epidemiology (2019-2032)
Table 3: AREDS Risk Factor Scoring System
Table 4: Drusen Classification
Table 5: Properties of Anti-VEGF Agents
Table 6: Total Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Table 7: Type-specific Diagnosed Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Table 8: Total Prevalent Cases of AMD in the United States, in 000’ (2019-2032)
Table 9: Total Diagnosed Cases of AMD in the United States, in 000’ (2019-2032)
Table 10: Type-specific Cases of AMD in the United States, in 000’ (2019-2032)
Table 11: Total Age-specific Cases of Wet AMD in the United States, in 000’ (2019-2032)
Table 12: Total Diagnosed cases of Dry AMD by Age Distribution in the US in, 000’ (2019-2032)
Table 13: Total Diagnosed Dry AMD Cases by Stages in the US, 000’ (2019-2032)
Table 14: Total Geographic Atrophy Cases by Visual Impairment in the US, 000’ (2019-2032)
Table 15: Total Prevalent Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 16: Total Diagnosed Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 17: Type-specific Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 18: Total Age-specific Cases of Wet AMD in the EU-5, in 000’ (2019-2032)
Table 19: Total Diagnosed cases of Dry AMD by Age Distribution in EU5, 000’ (2019-2032)
Table 20: Total Diagnosed Dry AMD Cases by Stages in EU5, 000’ (2019-2032)
Table 21: Total Geographic Atrophy Cases by Visual Impairment in EU5, 000’ (2019-2032)
Table 22: Total Prevalent Cases of AMD in Germany, in 000’ (2019-2032)
Table 23: Total Diagnosed Cases of AMD in Germany, in 000’ (2019-2032)
Table 24: Type-specific Cases of AMD in Germany, in 000’ (2019-2032)
Table 25: Total Age-specific Cases of Wet AMD in Germany, in 000’ (2019-2032)
Table 26: Total Diagnosed cases of Dry AMD by Age Distribution in Germany, in 000’ (2019-2032)
Table 27: Total Diagnosed Dry AMD Cases by Stages in Germany, in 000’ (2019-2032)
Table 28: Total Geographic Atrophy Cases by Visual Impairment in Germany, in 000’ (2019-2032)
Table 29: Total Prevalent Cases of AMD in France, in 000’ (2019-2032)
Table 30: Total Diagnosed Cases of AMD in France, in 000’ (2019-2032)
Table 31: Type-specific Cases of AMD in France, in 000’ (2019-2032)
Table 32: Total Age-specific Cases of Wet AMD in France, in 000’ (2019-2032)
Table 33: Total Diagnosed cases of Dry AMD by Age Distribution in France, in 000’ (2019-2032)
Table 34: Total Diagnosed Dry AMD Cases by Stages in France, in 000’ (2019-2032)
Table 35: Total Geographic Atrophy Cases by Visual Impairment in France, in 000’ (2019-2032)
Table 36: Total Prevalent Cases of AMD in Italy, in 000’ (2019-2032)
Table 37: Total Diagnosed Cases of AMD in Italy, in 000’ (2019-2032)
Table 38: Type-specific Cases of AMD in Italy, in 000’ (2019-2032)
Table 39: Total Age-specific Cases of Wet AMD in Italy, in 000’ (2019-2032)
Table 40: Total Diagnosed cases of Dry AMD by Age Distribution in Italy, in 000’ (2019-2032)
Table 41: Total Diagnosed Dry AMD Cases by Stages in Italy, in 000’ (2019-2032)
Table 42: Total Geographic Atrophy Cases by Visual Impairment in Italy, in 000’ (2019-2032)
Table 43: Total Prevalent Cases of AMD in Spain, in 000’ (2019-2032)
Table 44: Total Diagnosed Cases of AMD in Spain, in 000’ (2019-2032)
Table 45: Type-specific Cases of AMD in Spain, in 000’ (2019-2032)
Table 46: Total Age-specific Cases of Wet AMD in Spain, in 000’ (2019-2032)
Table 47: Total Diagnosed cases of Dry AMD by Age Distribution in Spain, in 000’ (2019-2032)
Table 48: Total Diagnosed Dry AMD Cases by Stages in Spain, in 000’ (2019-2032)
Table 49: Total Geographic Atrophy Cases by Visual Impairment in Spain, in 000’ (2019-2032)
Table 50: Total Prevalent Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 51: Total Diagnosed Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 52: Type-specific Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 53: Total Age-specific Cases of Wet AMD in the United Kingdom, in 000’ (2019-2032)
Table 54: Total Diagnosed cases of Dry AMD by Age Distribution in the United Kingdom, in 000’ (2019-2032)
Table 55: Total Diagnosed Dry AMD Cases by Stages in the United Kingdom, in 000’ (2019-2032)
Table 56: Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom, in 000’ (2019-2032)
Table 57: Total Prevalent Cases of AMD in Japan, in 000’ (2019-2032)
Table 58: Total Diagnosed Cases of AMD in Japan, in 000’ (2019-2032)
Table 59: Type-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Table 60: Total Age-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Table 61: Total Diagnosed cases of Dry AMD by Age Distribution in Japan, 000’ (2019-2032)
Table 62: Total Diagnosed Dry AMD Cases by Stages in Japan, 000’ (2019-2032)
Table 63: Total Geographic Atrophy Cases by Visual Impairment in Japan, 000’ (2019-2032)
List of Figures
Figure 1: Dry and wet AMD
Figure 2: Cellular Senescence contributing to AMD
Figure 3: Inflammation in AMD
Figure 4: Total Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Figure 5: Type-specific Diagnosed Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Figure 6: Total Prevalent Cases of AMD in the United States, in 000’ (2019-2032)
Figure 7: Total Diagnosed Cases of AMD in the United States, in 000’ (2019-2032)
Figure 8: Type-specific Cases of AMD in the United States, in 000’ (2019-2032)
Figure 9: Total Age-specific Cases of Wet AMD in the United States, in 000’ (2019-2032)
Figure 10: Total Diagnosed cases of Dry AMD by Age Distribution in the US in, 000’ (2019-2032)
Figure 11: Total Diagnosed Dry AMD Cases by Stages in the US, 000’ (2019-2032)
Figure 12: Total Geographic Atrophy Cases by Visual Impairment in the US, 000’ (2019-2032)
Figure 13: Total Prevalent Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 14: Total Diagnosed Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 15: Type-specific Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 16: Total Age-specific Cases of Wet AMD in the EU-5, in 000’ (2019-2032)
Figure 17: Total Diagnosed cases of Dry AMD by Age Distribution in EU5, 000’ (2019-2032)
Figure 18: Total Diagnosed Dry AMD Cases by Stages in EU5, 000’ (2019-2032)
Figure 19: Total Geographic Atrophy Cases by Visual Impairment in EU5, 000’ (2019-2032)
Figure 20: Total Prevalent Cases of AMD in Germany, in 000’ (2019-2032)
Figure 21: Total Diagnosed Cases of AMD in Germany, in 000’ (2019-2032)
Figure 22: Type-specific Cases of AMD in Germany, in 000’ (2019-2032)
Figure 23: Total Age-specific Cases of Wet AMD in Germany, in 000’ (2019-2032)
Figure 24: Total Diagnosed cases of Dry AMD by Age Distribution in Germany, in 000’ (2019-2032)
Figure 25: Total Diagnosed Dry AMD Cases by Stages in Germany, in 000’ (2019-2032)
Figure 26: Total Geographic Atrophy Cases by Visual Impairment in Germany, in 000’ (2019-2032)
Figure 27: Total Prevalent Cases of AMD in France, in 000’ (2019-2032)
Figure 28: Total Diagnosed Cases of AMD in France, in 000’ (2019-2032)
Figure 29: Type-specific Cases of AMD in France, in 000’ (2019-2032)
Figure 30: Total Age-specific Cases of Wet AMD in France, in 000’ (2019-2032)
Figure 31: Total Diagnosed cases of Dry AMD by Age Distribution in France, in 000’ (2019-2032)
Figure 32: Total Diagnosed Dry AMD Cases by Stages in France, in 000’ (2019-2032)
Figure 33: Total Geographic Atrophy Cases by Visual Impairment in France, in 000’ (2019-2032)
Figure 34: Total Prevalent Cases of AMD in Italy, in 000’ (2019-2032)
Figure 35: Total Diagnosed Cases of AMD in Italy, in 000’ (2019-2032)
Figure 36: Type-specific Cases of AMD in Italy, in 000’ (2019-2032)
Figure 37: Total Age-specific Cases of Wet AMD in Italy, in 000’ (2019-2032)
Figure 38: Total Diagnosed cases of Dry AMD by Age Distribution in Italy, in 000’ (2019-2032)
Figure 39: Total Diagnosed Dry AMD Cases by Stages in Italy, in 000’ (2019-2032)
Figure 40: Total Geographic Atrophy Cases by Visual Impairment in Italy, in 000’ (2019-2032)
Figure 41: Total Prevalent Cases of AMD in Spain, in 000’ (2019-2032)
Figure 42: Total Diagnosed Cases of AMD in Spain, in 000’ (2019-2032)
Figure 43: Type-specific Cases of AMD in Spain, in 000’ (2019-2032)
Figure 44: Total Age-specific Cases of Wet AMD in Spain, in 000’ (2019-2032)
Figure 45: Total Diagnosed cases of Dry AMD by Age Distribution in Spain, in 000’ (2019-2032)
Figure 46: Total Diagnosed Dry AMD Cases by Stages in Spain, in 000’ (2019-2032)
Figure 47: Total Geographic Atrophy Cases by Visual Impairment in Spain, in 000’ (2019-2032)
Figure 48: Total Prevalent Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 49: Total Diagnosed Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 50: Type-specific Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 51: Total Age-specific Cases of Wet AMD in the United Kingdom, in 000’ (2019-2032)
Figure 52: Total Diagnosed cases of Dry AMD by Age Distribution in the United Kingdom, in 000’ (2019-2032)
Figure 53: Total Diagnosed Dry AMD Cases by Stages in the United Kingdom, in 000’ (2019-2032)
Figure 54: Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom, in 000’ (2019-2032)
Figure 55: Total Prevalent Cases of AMD in Japan, in 000’ (2019-2032)
Figure 56: Total Diagnosed Cases of AMD in Japan, in 000’ (2019-2032)
Figure 57: Type-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Figure 58: Total Age-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Figure 59: Total Diagnosed cases of Dry AMD by Age Distribution in Japan, 000’ (2019-2032)
Figure 60: Total Diagnosed Dry AMD Cases by Stages in Japan, 000’ (2019-2032)
Figure 61: Total Geographic Atrophy Cases by Visual Impairment in Japan, 000’ (2019-2032)

Related Topics

Related Reports

Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024 - Product Image

Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Macular Degeneration Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029 - Product Image

Macular Degeneration Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • Report
  • 131 Pages
  • Global
From
Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Macular Degeneration Treatment Global Market Report 2024 - Product Image

Macular Degeneration Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
Copyright © 2002-2024 Research and Markets. All Rights Reserved.